

CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia

Laura Carrillo-Serradell,^{1,2} * Juan Antonio Piñeyroa,^{2-4*} Pablo Bousquets-Muñoz,^{5,6} Violeta Planells-Romeo,^{1,2} Lucía Aragón-Serrano,^{1,2} Sergi Casadó-Llombart,¹ Dolors Colomer,^{4,6-8} María Velasco-de Andrés,¹ Xose S. Puente,^{5,6} Julio Delgado,^{3,6,9,10} Pablo Mozas^{3,9#} and Francisco Lozano^{1,11,12#}

¹Immunoreceptors del Sistema Innat i Adaptatiu, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; ²Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona; ³Servei d’Hematologia, Hospital Clínic de Barcelona, Barcelona; ⁴Terapias Experimentales en Neoplasias Linfoides, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; ⁵Instituto de Oncología, Departamento de Bioquímica y Biología Molecular, Universidad de Oviedo, Oviedo; ⁶Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid; ⁷Secció Hematopatologia, Servei Anatomia Patològica, Centre Diagnòstic Biomèdic (CDB), Hospital Clínic Barcelona, Barcelona; ⁸Departament de Fonaments Clínics, Universitat de Barcelona (UB), Barcelona; ⁹Neoplasies Limfoides, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; ¹⁰Departament de Medicina, Universitat de Barcelona, Barcelona; ¹¹Servei d’Immunologia, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic Barcelona, Barcelona and ¹²Departament de Biomedicina, Universitat de Barcelona, Barcelona, Spain

**LC-S and JAP contributed equally as first authors.*
#PM and FL contributed equally as senior authors.

Correspondence: F. Lozano
flozano@clinic.cat

P. Mozas
mozas@clinic.cat

Received: February 13, 2025.
Accepted: June 25, 2025.
Early view: July 3, 2025.

<https://doi.org/10.3324/haematol.2025.287564>

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license 

Supplementary figures




Figure S1. Time to first treatment cumulative incidence curve and multivariable analysis of time to first treatment based on mRNA *CD6* median expression.




Figure S2. Forest plot analysis including only IGHV status and *CD6* level to predict time to first treatment.




Figure S3. Comparison of CD38 and CD49d / ITGA4 expression in the *CD6^{lo}* and *CD6^{hi}* CLL patient subgroups measured by flow cytometry. Statistical significances were assessed by means of Mann-Whitney test. *, $p < 0.05$.




Figure S4. Time to first treatment and overall survival based on mRNA *CD6* expression for the entire cohort.

Supplementary tables

Table S1. Demographics and disease features of the cases included in the flow cytometry assessment of CD6.						
Case number	Age (year)	Sex	Diagnosis	Binet stage	CD6 mRNA expression (TPM)	CD6 Subgroup
16	58	Male	CLL	A	210,6162	CD6 ^{hi}
131	68	Male	CLL	A	137,9907	CD6 ^{hi}
1292	61	Male	CLL	A	125,8629	CD6 ^{hi}
749	46	Male	CLL	A	117,0755	CD6 ^{hi}
442	61	Male	CLL	A	115,2558	CD6 ^{hi}
689	61	Female	CLL	A	109,9161	CD6 ^{hi}
270	70	Male	CLL	A	108,4679	CD6 ^{hi}
142	43	Male	CLL	A	100,8533	CD6 ^{hi}
811	84	Male	CLL	A	95,1694	CD6 ^{hi}
473	50	Female	CLL	A	86,8506	CD6 ^{hi}
1185	53	Male	CLL	A	84,4923	CD6 ^{hi}
381	66	Male	CLL	A	77,3495	CD6 ^{lo}
172	62	Female	CLL	A	77,2707	CD6 ^{lo}
176	75	Male	CLL	A	76,0441	CD6 ^{lo}
159	65	Male	CLL	A	75,1333	CD6 ^{lo}
1323	63	Female	CLL	A	74,8295	CD6 ^{lo}
561	69	Male	CLL	A	46,1781	CD6 ^{lo}
192	73	Female	CLL	A	44,8788	CD6 ^{lo}
523	71	Female	CLL	A	41,3063	CD6 ^{lo}
3	40	Male	CLL	C	34,9303	CD6 ^{lo}
306	60	Male	CLL	B	34,9199	CD6 ^{lo}
1448	69	Female	CLL	A	32,3892	CD6 ^{lo}
371	81	Female	CLL	A	29,4494	CD6 ^{lo}
754	73	Male	MBL	A	23,1616	CD6 ^{lo}
316	77	Male	CLL	A	11,8232	CD6 ^{lo}
1534	69	Male	CLL	B	5,1299	CD6 ^{lo}